Skip to main content
SpringerLink
Log in

Twenty-four hour tolbutamide plasma concentration as a phenotypic measure of CYP2C9 activity

  • Letter to the Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ (1990) Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 47:403–411

    CAS  PubMed  Google Scholar 

  2. Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA (2003) Tolbutamide, flurbiprofen and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol 43:84–91

    Article  CAS  PubMed  Google Scholar 

  3. Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA (2002) Evaluation of CYP2C9 metabolic activity with tolbutamide in CYP2C9*1 heterozygotes. Clin Pharmacol Ther 72:562–571

    Article  CAS  PubMed  Google Scholar 

  4. Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meise C, et al (2002) Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 12:101–109

    Article  CAS  PubMed  Google Scholar 

  5. Jetter A, Kinzig-Schippers M, Skott A, Lazar A, Tomalik-Scharte D, Kirchheiner J, et al (2004) Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol 60:165–171

    Article  CAS  PubMed  Google Scholar 

  6. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, et al (2004) Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 14:527–537

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge Dr. Alan Hinderliter, Ms. Joyce Blaisdell, Dr. Joyce Goldstein, and the nursing staff of the UNC General Clinical Research Center for their help in performing the study. This investigation was supported in part by grant RR00046 from the General Clinical Research Centers program of the Division of Research Resources, National Institutes of Health.

Author information

Authors and Affiliations

  1. Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, CB# 7360, Kerr Hall, Chapel Hill, NC, 27599-7360, USA

    Craig R. Lee & Roy L. Hawke

  2. College of Pharmacy, University of New Mexico, Albuquerque, NM, USA

    John A. Pieper

Authors
  1. Craig R. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roy L. Hawke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John A. Pieper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Craig R. Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, C.R., Hawke, R.L. & Pieper, J.A. Twenty-four hour tolbutamide plasma concentration as a phenotypic measure of CYP2C9 activity. Eur J Clin Pharmacol 61, 315–316 (2005). https://doi.org/10.1007/s00228-005-0922-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-005-0922-9

Keywords

Search

Navigation